Kyle, Robert A <br/><br/>
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.  [electronic resource] 

 -  Cancer  May 2009 
 - 2155-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.24221  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carmustine--adverse effects<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Interferon Type I--administration & dosage<br/>Male<br/>Melphalan--adverse effects<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Prednisone--adverse effects<br/>Recombinant Proteins<br/>Survival Rate<br/>Vincristine--adverse effects